Skip to content

Inhibitory effect of Black ginger on Midazolam metabolism

Inhibitory effect of Black ginger treatment on CYP3A-mediated Midazolam metabolism in Japanese healthy volunteers - BGMDZ

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031180012
Enrollment
6
Registered
2018-07-23
Start date
2018-08-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

The oral administration of Midazolam and black ginger to healthy adult male

Sponsors

Namba Hokuto
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: We determine persons who are obtained document agreement by free will after the explanation using informed consent form, satisfy all of the following selection criteria, do not conflict with exclusion criteria, have been judged to be eligible for participation in this study by the research doctor as subjects. 1) Age: Age at agreement acquisition is between 20years old and under 45 years old 2) Gender: Male 3) Persons who have the ability to consent, protect compliance matters during this study, have screening inspection prescribed in this study plan, and can complain about subjective symptoms. 4) After screening inspection prescribed in this study plan, persons who has been judged to be eligible for participation in this study by the research doctor

Exclusion criteria

Exclusion criteria: We exclude persons who corresponding to any of the following criteria from this study. 1) Medical history that may have an impact on the evaluation and safety of this study (substance abuse, drug dependence, alcohol abuse, alcohol dependence, heart, liver, kidney, lung, eye, blood disorder etc.) 2) Drug that may have an impact on the evaluation and safety of this study (including supplement and health supplement) 3) History of drug allergy 4) Using excessive alcohol regularly (person can`t keep abstinence during the dosing test) 5) Within three months from other clinical trails 6) Persons who has been judged unsuitable as subjects of this study by the research doctor

Design outcomes

Primary

MeasureTime frame
Pharmacokinetic parameters of serum midazolam

Secondary

MeasureTime frame
Sedation after oral midazolam administration

Contacts

Public ContactHokuto Namba

Showa University Karasuyama Hospital

hokuto-n@med.showa-u.ac.jp+81-3-3300-5247

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026